Sun Pharmaceutical Industries Limited has scheduled a Board of Directors meeting on 22 May 2026. The primary agenda includes the review and approval of the company’s audited standalone and consolidated financial results for the quarter and year ended 31 March 2026. Additionally, the Board will deliberate on recommending a final dividend for the fiscal year 2025-26 for consideration by shareholders at the upcoming Annual General Meeting.
Upcoming Board Meeting Details
Sun Pharmaceutical Industries Limited has formally announced that its Board of Directors is set to convene on Friday, 22 May 2026. The meeting serves as a critical event for stakeholders, as the leadership team will evaluate the financial performance of the company for both the final quarter and the full fiscal year concluding on 31 March 2026.
Dividend Proposals
Beyond the review of financial results, the Board is expected to discuss the distribution of a final dividend to equity shareholders for the 2025-26 financial year. Any recommendation made by the Board during this meeting will subsequently be placed before the shareholders for formal approval at the company’s ensuing Annual General Meeting.
Trading Window Update
In accordance with corporate governance protocols, the company has confirmed that the trading window for its securities has been closed since 01 April 2026. This restriction remains in effect and will continue through 24 May 2026 to ensure market integrity while material financial information is finalized and disclosed.
Source: BSE
